Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABLE-GLP1
2025-520802-37-00Phase 4Authorised
- Sponsor
- University of Naples Federico II
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide (2 arms), sponsored by University of Naples Federico II. Primary endpoint: Change in inflammatory and endothelial biomarkers. Planned start Sep 2025; status: authorised.
02
Drugs
Beyond the preview
Go deeper on 2025-520802-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520802-37-00.